AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31045465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27682324 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 1993–2000
Number of subjects: 3074
Study 27682324 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 1997–2004
Number of subjects: 3074
Study 27682324 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 2000–2006
Number of subjects: 3074
Study 27682324 — intervention group
Group type: EXPERIMENTAL
Intervention: Men and women
Number of subjects: 3074
Study 27682324 — intervention group
Group type: EXPERIMENTAL
Intervention: Young-old adults (aged 60–74)
Number of subjects: 3074
Study 27682324 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural areas
Number of subjects: 3074
Study 27682324 — intervention group
Group type: EXPERIMENTAL
Intervention: Transferring
Number of subjects: 3074
Study 27682324 — intervention group
Group type: EXPERIMENTAL
Intervention: Bathing
Number of subjects: 3074
Study 27682324 — intervention group
Group type: EXPERIMENTAL
Intervention: Toileting
Number of subjects: 3074
Study 27682324 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing
Number of subjects: 3074
Study 27682324 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding
Number of subjects: 3074
Study 25853236 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol-Valsartan combination (20/320 mg)
Number of subjects: 30
Study 25853236 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (20 mg)
Number of subjects: 30
Study 25853236 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (320 mg)
Number of subjects: 30
Study 23419343 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg oral morphine sulphate
Number of subjects: 60
Study 23419343 — intervention group
Group type: COMPARATOR
Intervention: 0.05 mg/kg oral midazolam (active placebo)
Number of subjects: 60
Study 21290145 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise testing (GXT) in CHF patients
Number of subjects: 15
Study 21290145 — intervention group
Group type: COMPARATOR
Intervention: Graded exercise testing (GXT) in healthy subjects (HS)
Number of subjects: 15
Study 21290145 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise testing (GXT)
Number of subjects: 15
Study 18641099 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution CT scan findings in symptomatic SSc patients
Number of subjects: 162
Study 18641099 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 162
Study 18641099 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution CT scan findings in lcSSc patients
Number of subjects: 162
Study 18641099 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution CT scan findings in dcSSc patients
Number of subjects: 162
Study 18641099 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of PF extent with pulmonary function tests
Number of subjects: 162
Study 18641099 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of pGGO with BAL fluid
Number of subjects: 162
Study 15942260 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-alone trials
Number of subjects: 0
Study 15942260 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepulse-pulse trials
Number of subjects: 0
Study 15942260 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepulse inhibition
Number of subjects: 0
Study 12582782 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine dihydrochloride (16 mg twice per day for 3 months)
Number of subjects: 144
Study 12582782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 10484854 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotterdam Symptom Checklist (RSCL) at week 1
Number of subjects: 52
Study 10484854 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotterdam Symptom Checklist (RSCL) at week 2
Number of subjects: 52
Study 10484854 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotterdam Symptom Checklist (RSCL) at week 3
Number of subjects: 52
Study 10484854 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of RSCL scores between weeks 1 and 3
Number of subjects: 52
Study 10484854 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of RSCL scores between weeks 1 and 2
Number of subjects: 52
Study 8607394 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 97
Study 8607394 — intervention group
Group type: COMPARATOR
Intervention: Propafenone
Number of subjects: 97
Study 2006246 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg PO)
Number of subjects: 8
Study 2006246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7020609 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-valent pneumococcal polysaccharide vaccine
Number of subjects: 871
Study 7020609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 871
Study 30506109 — intervention group
Group type: EXPERIMENTAL
Intervention: Early replacement (ER) group received FXIII concentrate the day after randomization.
Number of subjects: 50
Study 30506109 — intervention group
Group type: COMPARATOR
Intervention: Control group received no FXIII concentrate within 2 weeks.
Number of subjects: 50
Study 28797305 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy (VL) using cMac, dBlade, and King Vision
Number of subjects: 22
Study 28797305 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy (VL)
Number of subjects: 22
Study 28797305 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy (VL) with hyperangulated blade geometries
Number of subjects: 22
Study 26324089 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (GLP-1RA)
Number of subjects: 16
Study 26324089 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (SU)
Number of subjects: 16
Study 26324089 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (Glimepiride and Liraglutide)
Number of subjects: 16
Study 23151017 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose intolerance prevalence in girls (4.2%) vs boys (3.2%)
Number of subjects: 1519
Study 23151017 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent age group
Number of subjects: 1519
Study 23151017 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 1519
Study 23151017 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 1519
Study 23151017 — intervention group
Group type: EXPERIMENTAL
Intervention: Acanthosis nigricans
Number of subjects: 1519
Study 23151017 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of diabetes
Number of subjects: 1519
Study 23151017 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA-IR
Number of subjects: 1519
Study 23151017 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal obesity in girls
Number of subjects: 1519
Study 21873490 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum FGF23 levels
Number of subjects: 659
Study 18294116 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine, enalapril, and/or hydrochlorothiazide
Number of subjects: 0
Study 18294116 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with perindopril and indapamide
Number of subjects: 0
Study 18294116 — intervention group
Group type: COMPARATOR
Intervention: Candesartan or hydrochlorothiazide
Number of subjects: 0
Study 18294116 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone, atenolol, or reserpine
Number of subjects: 0
Study 16735187 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle functional MRI (mfMRI)
Number of subjects: 7
Study 15293527 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine (10-20 mg/day)
Number of subjects: 136
Study 15293527 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10-20 mg/day)
Number of subjects: 136
Study 11167479 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 60
Study 11167479 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 60
Study 9432100 — intervention group
Group type: EXPERIMENTAL
Intervention: Boxing training session in the laboratory (BOXL)
Number of subjects: 8
Study 9432100 — intervention group
Group type: EXPERIMENTAL
Intervention: Boxing training session in a boxing studio (BOXS)
Number of subjects: 8
Study 9432100 — intervention group
Group type: COMPARATOR
Intervention: Incremental running test on the treadmill
Number of subjects: 8
Study 8430919 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 14
Study 8430919 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol
Number of subjects: 14
Study 3319637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 90 mg/day
Number of subjects: 30
Study 3319637 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 240 mg/day
Number of subjects: 30
Study 30053856 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher vegetable intake (mean 324.6 ± 196.1 g/day)
Number of subjects: 187
Study 30053856 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher vegetable variety score (VVS)
Number of subjects: 187
Study 27245928 — intervention group
Group type: EXPERIMENTAL
Intervention: Water aerobics session (45 minutes at 70%-75% of maximum heart rate)
Number of subjects: 18
Study 27245928 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 18
Study 27245928 — intervention group
Group type: EXPERIMENTAL
Intervention: Water aerobics session
Number of subjects: 18
Study 27245928 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 24509968 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene-benzoyl peroxide topical gel
Number of subjects: 3855
Study 24509968 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 3855
Study 22882692 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccine
Number of subjects: 78
Study 22882692 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted vaccine
Number of subjects: 78
Study 22882692 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted vaccine (healthy controls)
Number of subjects: 78
Study 22882692 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccine (GMT)
Number of subjects: 78
Study 22882692 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted vaccine (GMT)
Number of subjects: 78
Study 22882692 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted vaccine (healthy controls, GMT)
Number of subjects: 78
Study 20360753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive support for implementation of electronic monitoring in 32 experimental pharmacies
Number of subjects: 57
Study 20360753 — intervention group
Group type: COMPARATOR
Intervention: Minimal implementation support in 25 control pharmacies
Number of subjects: 57
Study 20360753 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (intensive support)
Number of subjects: 57
Study 20360753 — intervention group
Group type: COMPARATOR
Intervention: Control group (minimal support)
Number of subjects: 57
Study 20360753 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 57
Study 18180628 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone/acetaminophen (25 mg/2500 mg/d)
Number of subjects: 118
Study 18180628 — intervention group
Group type: COMPARATOR
Intervention: Tramadol (200 mg/d)
Number of subjects: 118
Study 18180628 — intervention group
Group type: COMPARATOR
Intervention: Hydrocodone/acetaminophen
Number of subjects: 118
Study 18180628 — intervention group
Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 118
Study 15998652 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher calorie-TPN regimen (40 kcal/kg/day)
Number of subjects: 10
Study 15998652 — intervention group
Group type: COMPARATOR
Intervention: Lower calorie-TPN regimen (30 kcal/kg/day)
Number of subjects: 10
Study 12972172 — intervention group
Group type: EXPERIMENTAL
Intervention: LSG 1200 mg/day
Number of subjects: 264
Study 12972172 — intervention group
Group type: EXPERIMENTAL
Intervention: LSG 1500 mg/day
Number of subjects: 264
Study 12972172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 11093596 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental diet high in unsaturated fats, low in saturated fats with hypoallergenic foods
Number of subjects: 50
Study 11093596 — intervention group
Group type: COMPARATOR
Intervention: Control well-balanced diet
Number of subjects: 50
Study 8827124 — intervention group
Group type: EXPERIMENTAL
Intervention: Theatre production
Number of subjects: 77
Study 8827124 — intervention group
Group type: COMPARATOR
Intervention: Standard health education seminar
Number of subjects: 77
Study 8499043 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 20
Study 8499043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3945915 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoradiotherapy (heating tumor to 42-43.5 degrees C using electromagnetic waves at 915 MHz, total ionizing radiation dose of 40 Gy)
Number of subjects: 48
Study 3945915 — intervention group
Group type: COMPARATOR
Intervention: Control group (radiation therapy only)
Number of subjects: 48
Study 29566582 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei SD1-milk
Number of subjects: 124
Study 29566582 — intervention group
Group type: COMPARATOR
Intervention: Standard-milk (control)
Number of subjects: 124
Study 26859853 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time feedback + Traditional feedback (RTF + TF)
Number of subjects: 0
Study 26859853 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional feedback (TF)
Number of subjects: 0
Study 26859853 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 24261644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous haloperidol 1 mg/q8h
Number of subjects: 2145
Study 24261644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous haloperidol 2 mg/q8h
Number of subjects: 2145
Study 24261644 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9%)
Number of subjects: 2145
Study 21463024 — intervention group
Group type: EXPERIMENTAL
Intervention: Nap group
Number of subjects: 32
Study 21463024 — intervention group
Group type: COMPARATOR
Intervention: Wake group
Number of subjects: 32
Study 19345451 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-rich hydrolyzed protein (HP)
Number of subjects: 0
Study 19345451 — intervention group
Group type: COMPARATOR
Intervention: Standard casein protein (CP)
Number of subjects: 0
Study 16786252 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized proprioception facilitation exercise (CPFE)
Number of subjects: 81
Study 16786252 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed kinetic chain exercise (CKCE)
Number of subjects: 81
Study 16786252 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 81
Study 14981006 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ‐123 (ETA) alone
Number of subjects: 16
Study 14981006 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ‐123 (ETA) in combination with BQ‐788 (ETB)
Number of subjects: 16
Study 14981006 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ‐788 (ETB) alone
Number of subjects: 16
Study 14981006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11233584 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery participation offered upon return of the questionnaire
Number of subjects: 1000
Study 11233584 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lottery participation)
Number of subjects: 1000
Study 11233584 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery participation
Number of subjects: 1000
Study 9766765 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg t.i.d.) plus paroxetine (20 mg/day)
Number of subjects: 100
Study 9766765 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus paroxetine (20 mg/day)
Number of subjects: 100
Study 8142123 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy alone or radiotherapy combined with surgery and/or chemotherapy
Number of subjects: 130
Study 8142123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial chemotherapy
Number of subjects: 130
Study 3133924 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% medium chain triglyceride/50% long chain triglyceride lipid emulsion
Number of subjects: 51
Study 3133924 — intervention group
Group type: COMPARATOR
Intervention: 100% long chain triglyceride emulsion
Number of subjects: 51
Study 3133924 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 51
Study 31592513 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-alcohol (0.5%/70%)
Number of subjects: 3665
Study 31592513 — intervention group
Group type: COMPARATOR
Intervention: Iodine-alcohol (1%/70%)
Number of subjects: 3665
Study 29198192 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle cluster (high water and F&V consumption, high PA z scores)
Number of subjects: 5387
Study 29198192 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy lifestyle cluster (high soft drinks and screen time z scores, low water, F&V and PA z scores)
Number of subjects: 5387
Study 29198192 — intervention group
Group type: COMPARATOR
Intervention: Parental education levels
Number of subjects: 5387
Study 26253800 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered 4% lidocaine with 1:100,000 epinephrine buffered with 0.18 mL 8.4% sodium bicarbonate
Number of subjects: 88
Study 26253800 — intervention group
Group type: COMPARATOR
Intervention: Nonbuffered 4% lidocaine with 1:100,000 epinephrine
Number of subjects: 88
Study 22833593 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal down-stroke pattern
Number of subjects: 12
Study 22833593 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast down-stroke pattern
Number of subjects: 12
Study 22833593 — intervention group
Group type: EXPERIMENTAL
Intervention: Very fast down-stroke pattern
Number of subjects: 12
Study 22018299 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP-guided care
Number of subjects: 151
Study 22018299 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) management
Number of subjects: 151
Study 18292398 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE); n = 9
Number of subjects: 21
Study 18292398 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU); n = 12
Number of subjects: 21
Study 22360024 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECEDE educational model
Number of subjects: 72
Study 15995091 — intervention group
Group type: EXPERIMENTAL
Intervention: True TENS
Number of subjects: 74
Study 15995091 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 74
Study 11791098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza virus vaccine (CAIV-T) administered by intranasal spray
Number of subjects: 0
Study 11791098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11791098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza virus vaccine (CAIV-T)
Number of subjects: 0
Study 9579177 — intervention group
Group type: EXPERIMENTAL
Intervention: STIR sequences
Number of subjects: 23
Study 9579177 — intervention group
Group type: COMPARATOR
Intervention: SPIR sequences
Number of subjects: 23
Study 8736266 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg i.v.) alone
Number of subjects: 17
Study 8736266 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg i.v.) combined with arginine (0.5 g/kg i.v.)
Number of subjects: 17
Study 8736266 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting (3 or 4 days)
Number of subjects: 17
Study 8736266 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 17
Study 2523226 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxacurium chloride 62.5 micrograms kg‐1 (2.5 x ED95)
Number of subjects: 27
Study 2523226 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxacurium chloride 37.5 micrograms kg‐1 (1.5 x ED95)
Number of subjects: 27
Study 2523226 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg kg‐1
Number of subjects: 27
Study 2523226 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 50 micrograms kg‐1
Number of subjects: 27
Study 2523226 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxacurium chloride
Number of subjects: 27
Study 361333 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxprenolol 80 mg
Number of subjects: 20
Study 361333 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol 80 mg
Number of subjects: 20
Study 361333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30165858 — intervention group
Group type: COMPARATOR
Intervention: 6 repetition maximum (RM)
Number of subjects: 15
Study 30165858 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 repetition maximum (RM)
Number of subjects: 15
Study 26825017 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% normal saline at a dose of 1.5mlkg ‐1 h ‐1 for 12h before surgery
Number of subjects: 328
Study 26825017 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 328
Study 26825017 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 328
Study 24183068 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education intervention with audio CD containing information, relaxation, and positive imagery
Number of subjects: 84
Study 24183068 — intervention group
Group type: COMPARATOR
Intervention: Regularly treated control
Number of subjects: 84
Study 22027496 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention for six months
Number of subjects: 0
Study 20070744 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant placed in extraction socket
Number of subjects: 0
Study 18162832 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus (LGG) therapy for 4 weeks
Number of subjects: 21
Study 18162832 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 21